CD274 and head and neck squamous cell carcinoma: Further, the KEYNOTE-048 trial demonstrated that first-line pembrolizumab monotherapy was superior to cetuximab with chemotherapy in recurrent/metastatic HNSCC patients whose tumors express PDL1 [6].